Orthofix International appointed Vicente Trelles to a newly created position titled, Senior Vice President, World Wide Operations and Shares Services on April 1.
Trelles Joins Vaters At Orthofix

Trelles will report directly to Bob Vaters, the company’s Chief Operating Officer. Vaters noted that he has worked with Trelles in the past and is confident his experience in providing operational leadership for global companies and his knowledge of the medical device industry “will be key as we continue executing our operational efficiency and margin expansion objectives.”
The company told OTW that Vaters worked with Trelles at Inamed Corporation from 2002 to 2006 when it was sold to Allergan. The two also co-founded the private equity group Med Opportunity Partners and worked together from 2006 until Vaters join Orthofix in 2008.
Trelles joins Orthofix with over 25 years of experience in the medical device and pharmaceutical industries. In addition to serving as partner of Med Opportunity Partners with Vaters, from 2001 to 2006, he was an Executive Vice President and Chief Operations Officer at Inamed Corporation. Prior to Inamed, Trelles held several executive positions with Allergan, Baxter Healthcare and American Hospital Supply in Europe and the United States.
Trelles has been granted an initial award of stock options to purchase 150, 000 shares of the company’s common stock at an exercise price of $33.01 per share. The company’s stock has been trading between $28 to $33 over the past three months. These options will vest in one-third annual increments beginning on the first anniversary of his date of employment.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.